A Phase III, Multicentre, Randomised, Open-label Study to Compare the Efficacy and Safety of AZD0486 Plus Rituximab Versus Chemotherapy Plus Rituximab in Previously Untreated Participants With Follicular Lymphoma (SOUNDTRACK-F1)
A Phase III, Multicentre, Randomised, Open-label Study to Compare the Efficacy and Safety of AZD0486 Plus Rituximab Versus Chemotherapy Plus Rituximab in Previously Untreated Participants With Follicular Lymphoma (SOUNDTRACK-F1)
This is a global, randomised, Phase III, multicentre, open-label study evaluating the efficacy, safety and the degree of added benefit of the Surovatamig (AZD0486) plus rituximab combination compared to Investigator's choice of 3 standard immunochemotherapy regimen, conducted in participants with untreated FL.
The study consists of 2 sequential parts.
Safety Run-in - this part will compare dose levels of Surovatamig (AZD0486) in combination with rituximab in order to establish the RP3D.
Phase III - The Phase III part will assess the superiority of Surovatamig (AZD0486) at RP3D in combination with rituximab, compared to Investigator's choice between 3 standard chemoimmunotherapy regimens. Phase 3 consists of 3 arms
Inclusion Criteria:
The above is a summary, other inclusion criteria details may apply
Exclusion Criteria:
The above is a summary, other exclusion criteria details may apply
information.center@astrazeneca.com1-877-240-9479
Macquarie University, 2109, Australia
Chuo-shi, 409-3898, Japan
Hirakata-shi, 573-1191, Japan
Kurashiki-shi, 710-8602, Japan
Sunto-gun, 411-8777, Japan
Toyoake-shi, 470-1192, Japan
Jeonnam, 519-763, South Korea
Lukang Township, 505029, Taiwan